ArticleFrontiers in oncology2022

Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma.

Taihang Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.